BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

844 related articles for article (PubMed ID: 31355493)

  • 1. CAR T cells for brain tumors: Lessons learned and road ahead.
    Akhavan D; Alizadeh D; Wang D; Weist MR; Shepphird JK; Brown CE
    Immunol Rev; 2019 Jul; 290(1):60-84. PubMed ID: 31355493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
    Front Immunol; 2020; 11():594271. PubMed ID: 33224149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
    Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
    Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
    Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
    Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
    Front Immunol; 2018; 9():3062. PubMed ID: 30740109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Choi BD; Maus MV; June CH; Sampson JH
    Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
    Feldman L; Brown C; Badie B
    Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T-cell therapy: Full speed ahead.
    Sermer D; Brentjens R
    Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T-Cell Therapies in Glioblastoma: A First Look.
    Migliorini D; Dietrich PY; Stupp R; Linette GP; Posey AD; June CH
    Clin Cancer Res; 2018 Feb; 24(3):535-540. PubMed ID: 29158268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T Cell Therapy for Neuroblastoma.
    Richards RM; Sotillo E; Majzner RG
    Front Immunol; 2018; 9():2380. PubMed ID: 30459759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
    Abbott RC; Cross RS; Jenkins MR
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunobiology of chimeric antigen receptor T cells and novel designs.
    Walsh Z; Yang Y; Kohler ME
    Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-cells to treat brain tumors.
    Guzman G; Pellot K; Reed MR; Rodriguez A
    Brain Res Bull; 2023 May; 196():76-98. PubMed ID: 36841424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.